What is Entera Bio?
Entera Bio is a biopharmaceutical company dedicated to the development of orally delivered macromolecules, including peptides and therapeutic proteins. The company targets significant unmet medical needs, aiming to transform the standard of care by offering mini daily tablet formulations for peptide treatments. Its most advanced product candidates, EB613 for high-risk, post-menopausal osteoporosis and EB612 for hypoparathyroidism, are currently in clinical development, representing a significant step forward in patient-centric drug delivery.
How much funding has Entera Bio raised?
Entera Bio has raised a total of $7.5M across 1 funding round:
Debt
$7.5M
Debt (2016): $7.5M with participation from Pontifax
Key Investors in Entera Bio
Pontifax
Pontifax Venture Capital is a venture capital firm specializing in life sciences, focusing on groundbreaking innovations and transformative healthcare technologies. They actively support companies from early-stage research through clinical development, providing strategic guidance and capital.
What's next for Entera Bio?
The recent major strategic investment signals a pivotal growth phase for Entera Bio, likely enabling the company to advance its clinical pipeline and expand its research and development capabilities. This capital infusion is expected to accelerate the progression of EB613 and EB612 through clinical trials, potentially bringing these novel oral therapies closer to market. The company's focus on transforming the standard of care for conditions like osteoporosis and hypoparathyroidism positions it for substantial impact within the biopharmaceutical landscape.
See full Entera Bio company page
